Targovax announces resignation of Chief Financial Officer, Torbjørn Furuseth
Oslo, Norway 9 July 2021 – Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that Torbjørn Furuseth has notified the Company that he is resigning from his position as Chief Financial Officer to take a CEO position with a cancer diagnostics company. Oystein Soug, CEO of Targovax, said: “I would like to thank Torbjørn for his leadership, dedicated work and his valuable contributions to Targovax. He has played an important role in developing and executing our company’s strategy. Torbjørn’s